Abstract
Pembrolizumab plus enfortumab vedotin (Pem+EV) showed encouraging activity in first-line (1L) cisplatin-ineligible (cis-IE) patients with locally advanced or metastatic urothelial cancer (la/mUC) in the KEYNOTE-869/EV-103 trial. The objective is to estimate the budget impact of including Pem+EV to a US health plan formulary as a 1L therapy in cis-IE la/mUC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
